Daily Archives: March 31, 2021

In adults with active psoriatic arthritis, continued treatment with guselkumab was associated with skin clearance and joint symptom improvement through 2 years, according to long-term data from the phase 3 DISCOVER-2 study.

In DISCOVER-2 (ClinicalTrials.gov:NCT03158285), patients with active psoriatic arthritis (N=739) were randomly assigned to guselkumab 100mg every 4 or every 8 weeks for 2 years, or to placebo with crossover to guselkumab every 4 weeks at week 24 through 2 years. The study aimed to evaluate multiple clinical outcomes including joint and skin symptoms and radiographic progression in patients with psoriatic arthritis.

Results at week 100 showed that 76% of patients receiving guselkumab every 4 weeks and 74% of patients receiving treatment every 8 weeks achieved at least 20 percent improvement in the American College of Rheumatology (ACR20) response criteria. Findings also revealed that 56% and 55% of patients treated with guselkumab every 4 weeks and 8 weeks, respectively, achieved at least 50 percent improvement in ACR score. Moreover, low rates of radiographic progression of joint damage were observed in patients receiving guselkumabfrom week 52-100.

Among patients who had clinically meaningful skin involvement at baseline, 59% and 53% of patients treated with guselkumab every 4 weeks and 8 weeks, respectively, achieved complete skin clearance (Psoriasis Area Severity Index [PASI] 100). Additionally, 62% and 55% of patients receiving guselkumab every 4 and 8 weeks, respectively, achieved complete skin clearance as measured by the Investigator Global Assessment (IGA) score of 0.

The safety of guselkumab in patients with active psoriatic arthritis through 2 years was found to be comparable to safety at 6 months and 1 year and was consistent with the safety profile seen in patients with moderate to severe plaque psoriasis. No new safety signals were observed through week 112.

Full data from the DISCOVER-2 trial will be presented during the Innovations in Dermatology: Virtual Spring Conference, March 16 to 20, 2021.

Guselkumab, an interleukin-23 antagonist, is marketed under the trade nameTremfyaand is approved for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

New phase 3 data show first-in-class Tremfya(guselkumab) achieved complete skin clearance and favorable joint efficacy in adult patients with active psoriatic arthritis (PsA) through two years. [press release]. Spring House, PA: Janssen; March 16, 2021.

This article originally appeared on MPR

See the rest here:
Guselkumab Benefits Observed Through 2 Years in Psoriatic Arthritis Trial - Dermatology Advisor

MOUNTAIN VIEW, Calif., March 24, 2021 /PRNewswire/ --Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that its AditxtReprogrammingTM Therapeutics Division is preparing its therapeutic program for psoriasis for First-In-Human clinical trials. The trials, which are planned to begin in Q4 2021, will evaluate clinical safety and efficacy of Aditxt's new approach to reprogramming and retraining the immune system.

The Trials will be evaluating a nucleic acid-based technology named Apoptotic DNA Immunotherapy (ADi). Aditxt's ADitechnology utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissues (therapeutically induced immune tolerance) and is protected with approximately 90 U.S. and international patents. ADihas demonstrated efficacy in several pre-clinical disease models including psoriasis in which a reduction in skin thickening and scaling, and modulation of key protein markers were observed.

Aditxt has signed an agreement with a regulatory consultant based in Munich, Germany, which will play a central role in navigating the first AditxtReprogrammingTM therapeutic program through the clinical trial and regulatory process. The firm will work with the Aditxt's AditxtReprogrammingTM team to submit an Investigational New Drug application (IND) to the regulatory agency in Germany. Psoriasis is the first indication being targeted for clinical trial in the AditxtReprogrammingTM therapeutics pipeline. Other candidates that are advancing toward clinical trials include ADi for type 1 diabetes and skin allografting.

Amro Albanna, co-founder and Chief Executive Officer of Aditxt, stated, "this agreement represents a major step forward as we begin advancing ADi for psoriasis through the regulatory process and towards the start of clinical trials. Our co-founder and Chief Innovation Officer, Dr. Shahrokh Shabahang, and his product development team have experience working within the regulatory framework of both the U.S. and Europe and are leading all preparation, execution, regulatory and budgetary matters relating to Aditxt's planned 2021 Phase I/IIA clinical trials for psoriasis. We are excited to begin this phase of Aditxt's development after our initial focus on launching the AditxtScoreTM platform for monitoring the immune system."

For more information about AditxtReprogrammingTM, visit aditxt.com/.

About Aditx Therapeutics Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The Company's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The Company's immune reprogramming technology is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: http://www.aditxt.com

Forward-Looking StatementsCertain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated February 10, 2021, that was filed with the Securities and Exchange Commission under File No. 333-252711, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Aditxt

Homepage

View original post here:
Aditxt to Initiate First-In-Human Clinical Trials with its Therapeutics Programs in Psoriasis by Year-End - PRNewswire

In patients with psoriatic arthritis (PsA) receiving secukinumab, retention, remission, low disease activity (LDA), and response rates were significantly better for those who were bionaive after 6 and 12 months of treatment, according to study results published in Arthritis Care & Research (Hoboken). Researchers indicated high retention rates and good remission, LDA, and response rates of secukinumab, with overall effectiveness comparable to previous observational studies of tumor necrosis factor inhibitors.

Researchers sought to evaluate the overall real-life 12-month retention rates of secukinumab in European patients with PsA.

A longitudinal, observational study was conducted in 13 quality registries in rheumatology practices in the European Spondyloarthritis Research Collaboration Network (EuroSpA RCN).

The current study included data from patients with PsA who received secukinumab between May 2015 and December 2018 in 13 countries in EuroSpA RCN, including Sweden, Denmark, Switzerland, Italy, Spain, Czech Republic, Slovenia, Portugal, Norway, Finland, Iceland, Romania, and Turkey. Study inclusion criteria were participants aged at least 18 years at beginning of treatment, a PsA diagnosis according to a treating rheumatologist, and a registered start and, if relevant, stop date of receiving secukinumab.

The primary study outcome was overall 12-month secukinumab retention rates. Secondary study outcomes included overall 6-month retention rates, as well as remission, LDA, and response rates after 6 months and 12 months of treatment.

A total of 2017 patients with PsA who had received secukinumab for the first time were enrolled in the study. After 6 and 12 months of secukinumab, overall retention rates were 86% and 76%, respectively. Crude (LUNDEX-adjusted) 6-month remission/LDA rates for Disease Activity Index for Psoriatic Arthritis (DAPSA28), 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP), and Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), respectively. At 12 months, crude (LUNDEX-adjusted) remission/LDA rates for DAPSA28, DAS28-CRP, and SDAI were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively.

At 6 months, crude (LUNDEX-adjusted) American College of Rheumatology (ACR) 20/50/70 responses were 34%/19%/11% (29%/16%/9%), respectively. At 12 months, crude (LUNDEX-adjusted) ACR20/50/70 responses were 37%/21%/11% (24%/14%/7%). Further, the effectiveness of secukinumab was significantly better among biologic/targeted synthetic disease-modifying antirheumatic drug (b/ts DMARD)-naive patients and was similar over time since PsA diagnosis (<2 years, 2-4 years, and >4 years), varying significantly across the European registries.

Study limitations included lack of data on extra-articular inflammatory involvement, heterogeneity in baseline characteristics and secukinumab effectiveness across the registries, and missing data on disease states and response rates, which reduced generalizability of the findings.

Researchers concluded that the findings from this study may be taken into consideration when making treatment decisions in routine clinical care.

Disclosure: The EuroSpA collaboration was supported by Novartis. Please see the original reference for a full list of authors disclosures.

Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries. Arthritis Care Res (Hoboken). Published online January 18, 2021. doi:10.1002/acr.24560

Read the original here:
Drug Retention, Remission, and Response Rates of Secukinumab in Psoriatic Arthritis Analyzed in Europe - Rheumatology Advisor

Brandi Glanville. MediaPunch/Shutterstock

Big misunderstanding. Brandi Glanvilles face looked noticeably different during an appearance on Australias The Morning Show on March 25. After many outlets called out that the Real Housewives of Beverly Hills alum was unrecognizable and must have gone under the knife.

Glanville put plastic surgery rumors to bed once for all via Twitter. She shared a shocking photo of half of her badly burned and scabbed face, with patches of redness and blisters.

So this happened to me in December 2nd degree burns all over my face from an accident with a psoriasis light I am still healing & really didnt want to share these photos but since @DailyMail is attacking my looks here is the 411, she captioned the throwback photo.

The Drinking and Tweeting: And Other Brandi Blunders author added she felt forced into sharing her painful experience. Honestly its not something I wanted out there or I wanted to share all and it was so depressing but I just feel like I have to defend myself, Im still healing.

Leah Van Bryan, who stars in The Internet Ruined My Life, commented on the jarring image, writing, Omg Brandi you poor woman I hope youre ok, thats disgraceful what theyre doing to you.

Glanville responded to the comment, providing more details about how the accident happened in the first place.

Im OK but you know it happened in December. Im still swollen and having people attack my looks just makes me feel like I never wanna leave my house and I just want to cry.

She continued to explain that her her retinas were burned and her eyelashes burned off. It was so painful that she couldnt even open her eyes for three whole days.

The burns occurred after a miscommunication between the reality star and her doctor. While she was supposed to hold the light over her face for 17.3 seconds, Glanville mistakenly left it there for 17.3 minutes. She adds that the burns were completely my fault, it was supposed to help the psoriasis that was overtaking my face from stress.

The fashion designer opened up about her struggle with psoriasis, which is a chronic skin condition, back in a November 2020 on Instagram. For Friday the 13th Im sharing something scary! Psoriasis taking over my face & Im depressed about it. Thank God for masks, she captioned the car selfie, showing a flare up by her nose.

Link:
Brandi Glanville Burned Off Her Eyelashes After Accident With At-Home Psoriasis Treatment: Pic - Us Weekly

Theres so much to say about cannabis; from being a great treatment option for pain relief to its mood relaxation properties and lots more. Cannabis has been described as the new gold in the health and wellness sector because of its endless potentials. The potential has now extended to the prevention of hair loss and treatment of psoriasis.

Before getting to the solutions, we must talk about the problem and try to understand why it happens. For anyone to fully appreciate the value of CBD shampoo and other CBD products, one must understand the problem.

When people grow older, they experience a natural change with their hair that leads to hair loss. While some lose hair at a slower pace, others lose hair much faster (this happens for different reasons).

Hair loss cab also be hereditary, if older members of your family also lose hair, there is a greater chance that the same will happen to you. Stress and hormonal deficiencies are also major causes of hair loss. If you are experiencing hair loss you will agree that it is the most worrisome experience. If you havent experienced hair loss, you should actively think about how to prevent it from happening.

While there are numerous solutions for hair loss, CBD shampoo is taking the lead for many reasons. Firstly, due to the anti-anxiety properties in CBD, you will learn to relax your mind and body thus reducing stress that can cause hair loss.

CBD shampoo also contains anti-inflammatory properties that protects the base of your hair from hair loss. Now there are numerous remedies for hair loss available on the market but some of them are proven to be ineffective.

However with CBD shampoo you have a tested product that offers consistent hair treatment which protects your hair from the scalp to the tips. You can trust CBD shampoo because of its natural components which nourish the hair elements and strengthens it.

Photo by Adrian Fernndez via Unsplash

CBD contains different amino and fatty acids which are crucial nutrients for hair protection. With the shampoo made from CBD you will also get other minerals in large quantities that keep your hair healthy, lush and strong. But please remember that shampoo products are not meant to be used on a one-off basis as it is important that your hair feeds on CBD regularly. You want the hair to get used to the CBD nutrients and you want to use just enough to ensure that there are no subsequent breakages which will lead to hair loss again.

Psoriasis is referred to as an autoimmune disease that causes a persons skin to appear red, dry and scaly. You will find these red patches mostly on the elbows, knees and scalp (your hair region).

Some of the symptoms of psoriasis includes uncomfortable itchy sensations caused by skin irritation and a burning feeling on the skin that degenerates into sores. If left untreated, these issues may worsen and cause a bigger problem for the individual that leads to unpleasant looking skin.

RELATED: Could Cannabis Eliminate The High-Cost And High-Stakes Of Current Psoriasis Medicines?

However, these symptoms can gradually fade away with the application of CBD shampoo on the affected scalp areas. It is easier to apply he CBD shampoo on the scalp than it is to use CBD oils and other topical creams on your hair and head.

The CBD shampoo works effectively by renewing your scalp and restoring balance to your skins life cycle. Once the life cycle of your skin is balanced, you will start to observe improvements and healing from the scalp to the hair.

Photo by IRA_EVVA/Getty Images

While there is no cure for psoriasis, CBD shampoo does help to minimize the severe effects it has on your skin. You will see symptoms reduce and with support from CBD, your immune system will receive a boost thus preventing further outbreak.

If you have been diagnosed with psoriasis on your scalp then you need CBD shampoo for relief. But it is not enough just to have CBD shampoo as there are some things to consider which can either improve the CBD usage or impede it.

If you have a lot of thick hair on your head, it might cause the shampoo to settle on the hair and not get to the scalp (which is your skin area). This fact is the reason why those with little or no hair tend to enjoy the benefits of CBD shampoo for psoriasis more than those with full and thick hair.

RELATED: Is CBD The Secret Ingredient To A Perfect Hair Day?

Now if you have a thick hair, all hope is not lost. You just need to ensure that when applying the shampoo, it gets to the scalp and settles in there for a while.

If you are worried that the CBD shampoo will not be enough for the hair volume youve got then its okay to mix the shampoo with coconut oil. A mix of CBD shampoo and coconut oil is a viable treatment for psoriasis on the scalp.

You can also achieve greater results with CBD shampoo for psoriasis or hair loss by taking additional CBD supplements so the healing also starts from the inside out.

CBD shampoo is packed with anti-inflammatory properties that strengthens and revitalizes damaged hair. With this shampoo your hair gets all the necessary vitamins, proteins and amino acids needed to make your scalp stronger thus stimulating hair growth.

It should be noted that CBD shampoo also offers a wide range of benefits for those who suffer from psoriasis. The application of CBD shampoo on the skin gives the user an invigorating feeling that makes both hair and skin come alive again.

Traditional shampoo contains additives and fragrances that leaves your skin feeling dry and damaged. However with CBD shampoo, you get an effective yet gentle product that repairs your hair and revives your skin follicles. If you desire that supple moisturizing effect that comes with using a good shampoo, get CBD shampoo today!

This article originally appeared on Cannabis.net and has been reposted with permission.

Link:
Can CBD Shampoo Prevent Hair Loss And Treat Psoriasis? - The Fresh Toast

A new research study titled EU Psoriasis Drugs market successfully portrays the entire global scenario as well as a detailed analysis of various regional segments.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=11088

The EU Psoriasis Drugs market research includes an examination of the leading geographies, such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of Middle East & Africa) for the period of 2019 to 2028.

The study on the EU Psoriasis Drugs market is a detailed review and presentation of the global industrys drivers, constraints, opportunities, demand factors, market size, historical data forecasts, and trends from 2019 to 2028. The study also assists in the comprehension of global EU Psoriasis Drugs market dynamics and structure by defining and evaluating market segments, as well as forecasting global market size.

Top Participants in the EU Psoriasis Drugs Market

Johnson & Johnson (USA), Novartis International AG , Pfizer Inc, Merck and Co. Inc, Celgene Corporation, Janssen Biotech Inc, Stiefel Laboratories Inc, Takeda Pharmaceutical Company Limited , Amgenand AbbVie

EU Psoriasis Drugs Market Segmentation

A. By Drug type

I. PharmaceuticalsII. Biopharmaceuticals

B. By Route of Administration

I. TopicalII. Systemic

View Detail [emailprotected]https://insights10.com/product/eu-psoriasis-drugs-market-analysis/

Table Of Content of EU Psoriasis Drugs Market

1. EU Psoriasis Drugs Market OverviewA. Market Size2. EU Psoriasis Drugs Growth DriversA. Increasing public awarenessB. Approval of new drugs3. EU Psoriasis Drugs Segmentation.A. By Drug typeI. PharmaceuticalsII. BiopharmaceuticalsB. By Route of AdministrationI. TopicalII. Systemic4. EU Psoriasis Drugs Major Market ShareA. Market Analysis, Insights and Forecast by Revenue5. Competitive LandscapeA. Major PlayersB. Products in Pipeline6. Key Company ProfilesA. Novartis Company overview, Product & Services, Strategies & FinancialsB. Pfizer Company overview, Product & Services, Strategies & FinancialsC. Merck Company overview, Product & Services, Strategies & Financials7. Healthcare Policies and Regulatory Landscape.A. Policy Changes and Reimbursement Scenario8. Factors Driving Market GrowthA. Key Industry DevelopmentsB. Mergers and Acquisitions9. Market Opportunities and Future TrendsA. Market OpportunitiesB. Future Trends10. Conclusion

The report also looks at key players competitive environment in terms of product, value, financial situation, product portfolio, growth strategy, and regional presence. The study includes a value chain analysis and a SWOT analysis to address the issue of whether shareholders should concentrate their efforts and investments in the near future on the EU Psoriasis Drugs markets emerging segment. Furthermore, the report is a collective presentation of primary and secondary research findings.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

See original here:
EU Psoriasis Drugs Market with Thriving CAGR by 2019 to 2028 SoccerNurds - SoccerNurds

DataIntelo recently publishes an all-inclusive report on the Global Chronic Plaque Psoriasis Therapeutics Market providing a complete overview of the key aspects of the market. Chronic Plaque Psoriasis Therapeutics market report makes a robust assessment regarding the current market situation and its scope, which are anticipated to impact significantly on the performance of the market during the forecast period, 2020-2027. This report includes an in-depth analysis about the COVID-19 situation and its possible impact on the market in the next few years. The report contains XX pages, which provides a precise and detailed explanation of key components and their market expansion scope in the mentioned period. The key insights about the potential size, volume, and dynamics of the market as mentioned in the report is a vital guideline that would help clients to make informed decision about their business investment plans and strategies in the market.

As per the analysis, the global Chronic Plaque Psoriasis Therapeutics market was valued at USD XX million in 2019 and is projected to reach a value of USD XX million by the end of 2027, expanding at a CAGR of XX% during the forecast period.

Few of the key players mentioned in this report:

AbbvieNovartis InternationalPfizerMerckAstelllas PharmaGlaxoSmithKline

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=82193

The report covers a detailed study on key areas such as market size, scope, and growth opportunities of the global Chronic Plaque Psoriasis Therapeutics market by analyzing the market trend and data available for the period prior to 2019. From this analysis, the report draws several observations and deduces about the key factors that drive or restrain the market growth, which would have a wide impact on the development and expansion of the market during the forecast period. Moreover, it covers a range of opportunities and challenges prevailing in the market that will help clients to evaluate their investment strategies.

The global Chronic Plaque Psoriasis Therapeutics market report examine the major segments and sub-segmentations of the market that are classified as the product types, applications, and regions. In additional to the harsh economic impact of the COVID-19 outbreak, the report studies the dynamics of the market by analysis the key performance of each segments and the potential expansion scope of the segments in the coming years. Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the global Chronic Plaque Psoriasis Therapeutics market in terms of applications are thoroughly assessed in the report in a view to entail a broader picture of the market.

The report, published by DataIntelo, is the most reliable information as the study consists of a concise graphical representations, tables, and figures which allow the users to easily understand the key market position of sectors or segment without going through a deep study of the report. The tables and figures represent the latest update information that provides a broad picture of several market developments of the products and services over the last few years.

Customize Report and Inquiry for the Chronic Plaque Psoriasis Therapeutics market report @ https://dataintelo.com/enquiry-before-buying/?reportId=82193

The market report relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies. Additionally, this report includes market analysis from several global experts and analysts who have in-depth knowledge about the market. To ensure a complete framework of the market, it also adopts several research tools such as statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Global Chronic Plaque Psoriasis Therapeutics market by Products

ClinicalNon-ClinicalInactive

Global Chronic Plaque Psoriasis Therapeutics market by Applications

HospitalsAmbulatory Surgical CentersOthers

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=82193

The report mentions some key global players in the market and additional names of the players in the market can be included as per the clients request. Moreover, a customized or separate report can also be available according to the needs of clients. The report covers the recent development of players including merger & acquisition agreements, partnership or joint venture and latest products launches from the key manufacturers in the Chronic Plaque Psoriasis Therapeutics market. Please contact with our sales team, who will deliver reports that suits your necessities.

Competition Landscape

The report covers global aspect of the market, covering

North AmericaLatin AmericaEuropeAsia PacificMiddle East and Africa

About DataIntelo:

DataIntelo is a globally leading distributor of market research report that has experienced by dealing with more than 800+ global clients. We offer quality market research report and provide data that can help generate a totally new approach for our clients to help change the outlook of their investment and business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Originally posted here:
Chronic Plaque Psoriasis Therapeutics Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis-...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the company has been selected to the Fortune 2021 list of Best Workplaces in Health Care & Biopharma.

We are honored to receive this recognition, said Todd Zavodnick, Chief Executive Officer of Dermavant. As a biotech startup, we believe that listening to and investing in our employees needs has helped us build a strong and dedicated culture in which our values resonate. I am grateful for our hard-working, talented team whose unwavering focus on improving patients lives drives the company forward with a sense of compassion and camaraderie, especially during these unprecedented times.

To determine the 2021 Best Workplaces in Health Care & Biopharma, Great Place to Work, the global authority on workplace culture, analyzed confidential survey feedback representing more than 825,000 employees from companies across the health care and biopharma industry. Employees responded to over 60 survey questions describing the extent to which their companies create an experience of trust and the ability to reach full potential as part of the team, regardless of role.

About Dermavant

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavants focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The companys robust medical dermatology pipeline includes both late-stage and earlier-stage-development product candidates the company believes could address important immuno-dermatological conditions, including psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively. The company reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis. For more information, please visit http://www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).

2021 FORTUNE Media IP Limited. All rights reserved. Used under license.

Original post:
FORTUNE Names Dermavant One of the 2021 Best Workplaces in Health Care & Biopharma - Business Wire

New York, March 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Anti-Inflammatory Therapeutics Industry" - https://www.reportlinker.com/p06039956/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Anti-Inflammatory Therapeutics Market to Reach $135.5 Billion by 2027 - Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$135.5 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$67.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is readjusted to a revised 4.5% CAGR for the next 7-year period. - The U.S. Market is Estimated at $26.5 Billion, While China is Forecast to Grow at 7.3% CAGR - The Anti-Inflammatory Therapeutics market in the U.S. is estimated at US$26.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$27.7 Billion by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR. - Corticosteroids Segment to Record 4.2% CAGR - In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 3.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$12.4 Billion in the year 2020 will reach a projected size of US$16.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$18 Billion by the year 2027, while Latin America will expand at a 5.2% CAGR through the analysis period.

- Select Competitors (Total 42 Featured) -

Read the full report: https://www.reportlinker.com/p06039956/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Anti-Inflammatory Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Anti-Inflammatory Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Respiratory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Respiratory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Psoriasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Psoriasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Table 31: USA Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

JAPAN Table 43: Japan Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 46: Japan Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

CHINA Table 49: China Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: China 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 52: China Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: China Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: China 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

EUROPE Table 55: Europe Current & Future Analysis for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Anti-Inflammatory Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Europe 15-Year Perspective for Anti-Inflammatory Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 58: Europe Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 61: Europe Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: Europe Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Europe 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

FRANCE Table 64: France Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: France Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: France 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 67: France Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: France Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: France 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

GERMANY Table 70: Germany Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: Germany Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Germany 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 73: Germany Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Germany Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Germany 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

ITALY Table 76: Italy Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: Italy Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Italy 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 79: Italy Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 80: Italy Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 81: Italy 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

UNITED KINGDOM Table 82: UK Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: UK Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: UK 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

Table 85: UK Current & Future Analysis for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 86: UK Historic Review for Anti-Inflammatory Therapeutics by Indication - Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: UK 15-Year Perspective for Anti-Inflammatory Therapeutics by Indication - Percentage Breakdown of Value Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

SPAIN Table 88: Spain Current & Future Analysis for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: Spain Historic Review for Anti-Inflammatory Therapeutics by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Spain 15-Year Perspective for Anti-Inflammatory Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the Years 2012, 2020 & 2027

The rest is here:
Global Application Container Market to Reach $9.7 Billion by 2027 - Benzinga